[go: up one dir, main page]

YU2603A - New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical formulation - Google Patents

New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical formulation

Info

Publication number
YU2603A
YU2603A YU2603A YUP2603A YU2603A YU 2603 A YU2603 A YU 2603A YU 2603 A YU2603 A YU 2603A YU P2603 A YUP2603 A YU P2603A YU 2603 A YU2603 A YU 2603A
Authority
YU
Yugoslavia
Prior art keywords
antagonist
pharmaceutical formulation
new combination
receptor
serotonin agonist
Prior art date
Application number
YU2603A
Other languages
Serbo-Croatian (sh)
Inventor
Sukhwinder Jossan
Bjorn M. Nillson
Kjell S. Sakariassen
Jan Svartengren
Original Assignee
Biovitrum Ab.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum Ab. filed Critical Biovitrum Ab.
Publication of YU2603A publication Critical patent/YU2603A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

The invention relates to a method of preventing or treating a disease related to the 5-HT2C receptor and the 5-HT6 receptor, comprising administering to a human or animal subject in need thereof a 5-HT2C receptor agonist and a 5-HT6 receptor antagonist in sufficient amounts to provide a therapeutic affect. The invention also relates to a pharmaceutical composition comprising an effective amount of a combination of a 5-HT2C receptor agonist and a 5-HT6 receptor antagonist, and optionally a pharmaceutically acceptable carrier.
YU2603A 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical formulation YU2603A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0002754A SE0002754D0 (en) 2000-07-21 2000-07-21 New pharmaceutical combination formulation and method of treatment with the combination

Publications (1)

Publication Number Publication Date
YU2603A true YU2603A (en) 2006-05-25

Family

ID=20280577

Family Applications (1)

Application Number Title Priority Date Filing Date
YU2603A YU2603A (en) 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical formulation

Country Status (18)

Country Link
EP (1) EP1301476A1 (en)
JP (1) JP2004504376A (en)
KR (1) KR100845450B1 (en)
CN (1) CN1221254C (en)
AU (2) AU8273401A (en)
BR (1) BR0112661A (en)
CA (1) CA2411192A1 (en)
EA (1) EA006604B1 (en)
HU (1) HUP0301346A3 (en)
IL (1) IL154057A0 (en)
MX (1) MXPA03000548A (en)
NO (1) NO20030304L (en)
NZ (1) NZ523216A (en)
PL (1) PL360309A1 (en)
SE (1) SE0002754D0 (en)
WO (1) WO2002008178A1 (en)
YU (1) YU2603A (en)
ZA (1) ZA200210234B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
AU2002220051B2 (en) * 2000-11-02 2007-05-24 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
CN1321110C (en) * 2001-06-15 2007-06-13 弗·哈夫曼-拉罗切有限公司 4-Piperazinoindole Derivatives with 5-HT6 Receptor Affinity
BR0210411A (en) 2001-06-15 2004-08-17 Hoffmann La Roche 5-ht6 receptor affinity 4-piperazinylindole derivatives
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
PT1956004E (en) 2002-03-27 2012-08-31 Glaxo Group Ltd Quinoline derivatives and their use as 5-ht6 ligands
CL2004000826A1 (en) * 2003-04-25 2005-03-04 Pfizer USE OF AN AGONIST FOR THE 5-HT2C RECEPTOR TO PREPARE A USEFUL MEDICINAL PRODUCT IN THE TREATMENT OF URINARY INCONTINENCE CAUSED BY STRESS, WITH THE CONDITION THAT THE AGONIST IS NOT 1- [6-CHLORINE-5- (TRIFLUOROMETIL) -2- PIRIDINIL] PIPERAZINA (ORG-129
PL1558582T3 (en) 2003-07-22 2006-05-31 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
JP5173190B2 (en) 2004-08-25 2013-03-27 武田薬品工業株式会社 Preventive and therapeutic agent for stress urinary incontinence and screening method thereof
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
EP1976495A2 (en) * 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
WO2007132841A1 (en) 2006-05-16 2007-11-22 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
US20070293475A1 (en) * 2006-06-20 2007-12-20 Alcon Manufacturing Ltd. Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma
EP2020230B1 (en) * 2007-08-01 2011-01-19 Laboratorios del Dr. Esteve S.A. Combination of at least two 5-HT6-Ligands
WO2009063992A1 (en) 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited Condensed pyridine derivative and use thereof
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
UA100192C2 (en) 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
ME01835B (en) 2009-06-15 2014-12-20 Takeda Pharmaceuticals Co Pyrazinooxazepine derivatives
JPWO2011071136A1 (en) 2009-12-11 2013-04-22 アステラス製薬株式会社 Fibromyalgia treatment
MX388281B (en) 2015-06-12 2025-03-11 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
CA2992518A1 (en) 2015-07-15 2017-01-19 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
CN107628981B (en) * 2017-10-31 2019-07-30 威海市妇女儿童医院 A kind of cinnamoyl sulfonylindoline compounds and its application for preparing glaucoma medicine
JPWO2019131902A1 (en) 2017-12-27 2020-12-10 武田薬品工業株式会社 Remedies for stress urinary incontinence and fecal incontinence
CN111269165A (en) * 2018-12-05 2020-06-12 中国科学院大连化学物理研究所 Synthetic method of 3-arylsulfonyl indole derivative

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (en) * 1996-12-19 2002-12-28 Smithkline Beecham Plc New sulfonamide derivatives process for their preparation and pharmaceutical compositions containing them.
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
US6251893B1 (en) * 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII

Also Published As

Publication number Publication date
HUP0301346A2 (en) 2003-08-28
EA200300183A1 (en) 2003-08-28
SE0002754D0 (en) 2000-07-21
AU8273401A (en) 2002-02-05
HUP0301346A3 (en) 2005-05-30
BR0112661A (en) 2003-06-24
KR20030036599A (en) 2003-05-09
EA006604B1 (en) 2006-02-24
NZ523216A (en) 2005-05-27
CA2411192A1 (en) 2002-01-31
NO20030304L (en) 2003-03-12
CN1443162A (en) 2003-09-17
ZA200210234B (en) 2004-03-18
AU2001282734B2 (en) 2006-10-12
PL360309A1 (en) 2004-09-06
NO20030304D0 (en) 2003-01-20
EP1301476A1 (en) 2003-04-16
MXPA03000548A (en) 2004-04-05
WO2002008178A1 (en) 2002-01-31
HK1057536A1 (en) 2004-04-08
CN1221254C (en) 2005-10-05
IL154057A0 (en) 2003-07-31
KR100845450B1 (en) 2008-07-10
JP2004504376A (en) 2004-02-12

Similar Documents

Publication Publication Date Title
YU2603A (en) New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical formulation
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
ES2295609T3 (en) TIADIAZOLILPIPERAZINA DERIVATIVES USEFUL TO TREAT OR PREVENT A PAIN.
NO993520D0 (en) Dosage forms and methods for improving erectile dysfunction
HUP0204163A2 (en) Controlled-release composition containing opioid agonist and antagonist and process for its preparation
MX9801305A (en) Oral fast-dissolving compositions for dopamine agonists.
AP1818A (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
DE60327843D1 (en) MEDICAMENT FORMULATIONS WITH DELAYED RELEASE WITH A CARRIER PEPTIDE
IL128723A0 (en) Pharmaceutical compositions containing rar antagonists and rxr agonists
SE9900961D0 (en) Novel compounds
MY133503A (en) Selective iglur5 receptor antagonists for the treatment of migrane
SE9802208D0 (en) Novel compounds
MY144897A (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
AU9551201A (en) Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic diseasestates
EP1064966A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
MXPA01008993A (en) Combination treatment for depression and anxiety.
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
SE9903995D0 (en) New combination
SE9802209D0 (en) Novel compounds
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
GB9930077D0 (en) Medicaments
EP1064948A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
BR0005319A (en) Combined treatment for depression and anxiety
GB9930085D0 (en) Medicaments
EP1260221A3 (en) Combination treatment for depression and anxiety